GID4

Summary

GID4 (GID complex subunit 4 homolog, HGNC:28453) is a protein-coding gene on chromosome 17p11.2, encoding Glucose-induced degradation protein 4 homolog (Q8IVV7). Substrate-recognition subunit of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1.

The multiprotein Mediator complex is a coactivator required for activation of RNA polymerase II transcription by DNA bound transcription factors. The protein encoded by this gene is thought to be a subunit of the Mediator complex. This gene is located within the Smith-Magenis syndrome region on chromosome 17.

Source: NCBI Gene 79018 — RefSeq curated summary.

At a glance

• GWAS associations: 12
• Clinical variants (ClinVar): 30 total
• Druggable target: yes
• MANE Select transcript: NM_024052

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28453
Approved symbol	GID4
Name	GID complex subunit 4 homolog
Location	17p11.2
Locus type	gene with protein product
Status	Approved
Aliases	VID24
Ensembl gene	ENSG00000141034
Ensembl biotype	protein_coding
OMIM	617699
Entrez	79018

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 6 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000268719, ENST00000376345, ENST00000459843, ENST00000481836, ENST00000579871, ENST00000879496, ENST00000912958

RefSeq mRNA: 2 — MANE Select: NM_024052 NM_001411057, NM_024052

CCDS: CCDS11190, CCDS92267

Canonical transcript exons

ENST00000268719 — 6 exons

Exon	Start	End
ENSE00000946246	18045147	18045206
ENSE00000946248	18054127	18054234
ENSE00001157122	18065180	18068405
ENSE00001522647	18039408	18039902
ENSE00002785960	18061845	18061975
ENSE00002897542	18058868	18058969

Expression profiles

Bgee: expression breadth ubiquitous, 265 present calls, max score 95.18.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.9245 / max 123.1462, expressed in 1795 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
159778	6.7991	1748
159779	4.5838	1691
159780	0.5082	260
159777	0.0334	5

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	95.18	gold quality
right testis	UBERON:0004534	95.03	gold quality
sperm	CL:0000019	94.96	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	94.96	gold quality
nipple	UBERON:0002030	94.84	gold quality
saphenous vein	UBERON:0007318	94.69	gold quality
testis	UBERON:0000473	93.34	gold quality
male germ cell	CL:0000015	93.06	gold quality
body of tongue	UBERON:0011876	92.86	gold quality
penis	UBERON:0000989	92.75	gold quality
superior surface of tongue	UBERON:0007371	91.24	gold quality
urethra	UBERON:0000057	91.14	gold quality
secondary oocyte	CL:0000655	90.60	gold quality
cardia of stomach	UBERON:0001162	90.35	gold quality
tongue	UBERON:0001723	90.34	gold quality
pericardium	UBERON:0002407	90.12	gold quality
pons	UBERON:0000988	89.93	gold quality
pharyngeal mucosa	UBERON:0000355	89.70	gold quality
inferior vagus X ganglion	UBERON:0005363	89.70	gold quality
renal medulla	UBERON:0000362	89.46	gold quality
dorsal root ganglion	UBERON:0000044	89.31	gold quality
ventral tegmental area	UBERON:0002691	89.29	gold quality
trigeminal ganglion	UBERON:0001675	89.12	gold quality
synovial joint	UBERON:0002217	88.68	gold quality
subthalamic nucleus	UBERON:0001906	88.61	gold quality
superior vestibular nucleus	UBERON:0007227	88.43	gold quality
gastrocnemius	UBERON:0001388	88.33	gold quality
pylorus	UBERON:0001166	88.22	gold quality
hindlimb stylopod muscle	UBERON:0004252	88.21	gold quality
amniotic fluid	UBERON:0000173	88.14	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.09

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

224 targeting GID4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955

Literature-anchored findings (GeneRIF, showing 3)

• crystallographic analysis of human GID4 alone and in complex with various Pro/N-degrons (PMID:29632410)
• Recognition of the gluconeogenic enzyme, Pck1, via the Gid4 E3 ligase: An in silico perspective. (PMID:31883179)
• The hGID[GID4] E3 ubiquitin ligase complex targets ARHGAP11A to regulate cell migration. (PMID:39389782)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	GID4	ENSDARG00000079482
mus_musculus	Gid4	ENSMUSG00000018415
rattus_norvegicus	Gid4	ENSRNOG00000069998

Protein

Protein identifiers

Glucose-induced degradation protein 4 homolog — Q8IVV7 (reviewed: Q8IVV7)

Alternative names: Vacuolar import and degradation protein 24 homolog

All UniProt accessions (4): K4DI96, K7ELH7, K7ENE2, Q8IVV7

UniProt curated annotations — full annotation on UniProt →

Function. Substrate-recognition subunit of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1. Binds proteins and peptides with a Pro/N-degron consisting of an unmodified N-terminal Pro followed by a small residue, and has the highest affinity for the peptide Pro-Gly-Leu-Trp. Binds peptides with an N-terminal sequence of the type Pro-[Ala,Gly]-[Leu,Met,Gln,Ser,Tyr]-[Glu,Gly,His,Ser,Val,Trp,Tyr]. Does not bind peptides with an acetylated N-terminal Pro residue.

Subunit / interactions. Identified in the CTLH complex that contains GID4, RANBP9 and/or RANBP10, MKLN1, MAEA, RMND5A (or alternatively its paralog RMND5B), GID8, ARMC8, WDR26 and YPEL5. Within this complex, MAEA, RMND5A (or alternatively its paralog RMND5B), GID8, WDR26, and RANBP9 and/or RANBP10 form the catalytic core, while GID4, MKLN1, ARMC8 and YPEL5 have ancillary roles. Interacts with helicases DDX21 and DDX50.

Domain organisation. The first four residues of target peptides with a free N-terminal Pro (a Pro/N-degron) are bound inside a deep and narrow beta-barrel structure.

Similarity. Belongs to the GID4/VID24 family.

RefSeq proteins (2): NP_001397986, NP_076957* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR018618	GID4/10-like	Family

Pfam: PF09783

UniProt features (35 total): strand 9, mutagenesis site 6, turn 5, helix 5, site 3, region of interest 2, sequence conflict 2, compositionally biased region 2, chain 1

Structure

Experimental structures (PDB)

31 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
6CD9	X-RAY DIFFRACTION	1.55
6CCR	X-RAY DIFFRACTION	1.6
6CD8	X-RAY DIFFRACTION	1.6
6CDG	X-RAY DIFFRACTION	1.6
6WZZ	X-RAY DIFFRACTION	1.6
7U3J	X-RAY DIFFRACTION	1.64
6CCU	X-RAY DIFFRACTION	1.75
6CDC	X-RAY DIFFRACTION	1.75
6WZX	X-RAY DIFFRACTION	1.75
7U3H	X-RAY DIFFRACTION	1.8
9QDZ	X-RAY DIFFRACTION	1.8
7U3E	X-RAY DIFFRACTION	1.85
9QZG	X-RAY DIFFRACTION	1.9
7SLZ	X-RAY DIFFRACTION	1.97
7U3I	X-RAY DIFFRACTION	1.99
9QZI	X-RAY DIFFRACTION	2
9QDY	X-RAY DIFFRACTION	2.1
9QZH	X-RAY DIFFRACTION	2.19
7U3K	X-RAY DIFFRACTION	2.2
8V1P	X-RAY DIFFRACTION	2.21
7U3G	X-RAY DIFFRACTION	2.24
9QDX	X-RAY DIFFRACTION	2.26
9OK4	X-RAY DIFFRACTION	2.28
7U3L	X-RAY DIFFRACTION	2.29
7U3F	X-RAY DIFFRACTION	2.3
6CCT	X-RAY DIFFRACTION	2.4
8X7G	X-RAY DIFFRACTION	2.7
8X7H	X-RAY DIFFRACTION	2.9
7Q4Y	X-RAY DIFFRACTION	3.08
7Q50	X-RAY DIFFRACTION	3.16

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IVV7-F1	76.05	0.51

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 132 (interaction with the n-terminal pro (pro/n-degron) of proteins that are targeted for degradation); 237 (interaction with the n-terminal pro (pro/n-degron) of proteins that are targeted for degradation); 258 (interaction with the n-terminal pro (pro/n-degron) of proteins that are targeted for degradation)

Mutagenesis-validated functional residues (6):

Position	Phenotype
253	strongly decreased affinity for peptides with a pro/n-degron.
258	loss of interaction with peptides with a pro/n-degron.
273	loss of interaction with peptides with a pro/n-degron.
282	loss of interaction with peptides with a pro/n-degron.
132	loss of interaction with peptides with a pro/n-degron.
237	loss of interaction with peptides with a pro/n-degron.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9861718	Regulation of pyruvate metabolism

MSigDB gene sets: 186 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, RORA1_01, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, SHAFFER_IRF4_TARGETS_IN_ACTIVATED_B_LYMPHOCYTE, ATGTTAA_MIR302C, MCBRYAN_PUBERTAL_BREAST_4_5WK_DN, ATTACAT_MIR3803P, GNF2_CCNA1, TCCAGAT_MIR5165P, SHAFFER_IRF4_TARGETS_IN_ACTIVATED_DENDRITIC_CELL, GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS, RGAGGAARY_PU1_Q6, IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR, GOBP_PROTEIN_CATABOLIC_PROCESS, BOYLAN_MULTIPLE_MYELOMA_C_D_UP

GO Biological Process (1): proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)

GO Molecular Function (1): ubiquitin protein ligase activity (GO:0061630)

GO Cellular Component (2): ubiquitin ligase complex (GO:0000151), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Pyruvate metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
intracellular protein-containing complex	1
transferase complex	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

500 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GID4	RMND5A	Q9H871	942
GID4	ARMC8	Q8IUR7	941
GID4	GID8	Q9NWU2	934
GID4	WDR26	Q9H7D7	898
GID4	RMND5B	Q96G75	840
GID4	RANBP10	Q6VN20	812
GID4	MKLN1	Q9UL63	790
GID4	MAEA	Q7L5Y9	787
GID4	RANBP9	Q96S59	716
GID4	YPEL5	P62699	689
GID4	MDH2	P40926	591
GID4	FBP1	P09467	531
GID4	UBE2H	P37286	470
GID4	RNF182	Q8N6D2	470
GID4	PRPSAP2	O60256	417

IntAct

128 interactions, top by confidence:

A	B	Type	Score
BAIAP2	YWHAZ	psi-mi:“MI:0914”(association)	0.800
ARMC8	HTRA2	psi-mi:“MI:0914”(association)	0.750
CCDC120	AIP	psi-mi:“MI:0914”(association)	0.640
CRIPTO	AIP	psi-mi:“MI:0914”(association)	0.640
NDUFS6	NDUFS8	psi-mi:“MI:0914”(association)	0.640
RANBP10	MAEA	psi-mi:“MI:0914”(association)	0.640
RANBP9	YPEL5	psi-mi:“MI:0914”(association)	0.640
MPP2	LIN7A	psi-mi:“MI:0914”(association)	0.640
PRG2	YPEL5	psi-mi:“MI:0914”(association)	0.640
GID8	HTRA2	psi-mi:“MI:0914”(association)	0.610
INSL6	POTEF	psi-mi:“MI:0914”(association)	0.530
PRG3	ZNF324	psi-mi:“MI:0914”(association)	0.530
GPS2	DCTN6	psi-mi:“MI:0914”(association)	0.530
PIGT	ZNF609	psi-mi:“MI:0914”(association)	0.530
PRICKLE3	SIAH2	psi-mi:“MI:0914”(association)	0.530
BMP1	TLL1	psi-mi:“MI:0914”(association)	0.530
JPH4	ZSWIM8	psi-mi:“MI:0914”(association)	0.530
TIGD5	P4HA2	psi-mi:“MI:0914”(association)	0.530
EMILIN3	ZZEF1	psi-mi:“MI:0914”(association)	0.530

BioGRID (122): GID4 (Affinity Capture-RNA), GID4 (Affinity Capture-MS), GID4 (Affinity Capture-MS), GID4 (Affinity Capture-MS), GID4 (Affinity Capture-MS), GID4 (Affinity Capture-MS), GID4 (Affinity Capture-MS), GID4 (Affinity Capture-MS), GID4 (Affinity Capture-MS), GID4 (Affinity Capture-MS), GID4 (Affinity Capture-MS), GID4 (Affinity Capture-MS), GID4 (Affinity Capture-MS), GID4 (Affinity Capture-MS), GID4 (Affinity Capture-MS)

ESM2 similar proteins: A1YFY6, A2T6X9, A7Z026, B2RUJ5, B2RYF1, D4ABL6, M0R7T9, O08609, O09112, O35430, O35431, O35652, O35779, O60347, O75864, O77638, O88751, O88942, O95644, P20749, P81133, P98084, P98201, Q01201, Q02410, Q04863, Q0IHH1, Q0IHY4, Q13202, Q13469, Q14190, Q147X3, Q3TZ87, Q3UR85, Q5RD33, Q61045, Q61079, Q6A039, Q6DN14, Q7Z6J2

Diamond homologs: P38263, P53242, Q10079, Q8IVV7, Q9CPY6, Q9UT04

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 117 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of pyruvate metabolism	8	53.7×	4e-10
Mitochondrial translation	6	9.7×	5e-03
Mitochondrial translation initiation	6	9.0×	5e-03
Mitochondrial translation elongation	6	9.0×	5e-03
Mitochondrial ribosome-associated quality control	6	8.7×	5e-03
Mitochondrial translation termination	6	7.8×	8e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

30 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	25
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

811 predictions. Top by Δscore:

Variant	Effect	Δscore
17:18054232:TGGGT:T	donor_loss	1.0000
17:18054233:GG:G	donor_gain	1.0000
17:18054234:GG:G	donor_gain	1.0000
17:18054234:GGTG:G	donor_loss	1.0000
17:18054235:G:C	donor_loss	1.0000
17:18054235:G:GG	donor_gain	1.0000
17:18054236:TGA:T	donor_loss	1.0000
17:18054237:GAG:G	donor_loss	1.0000
17:18058863:TTCA:T	acceptor_loss	1.0000
17:18058864:TCA:T	acceptor_loss	1.0000
17:18058866:A:AG	acceptor_gain	1.0000
17:18058866:AG:A	acceptor_gain	1.0000
17:18058867:G:GG	acceptor_gain	1.0000
17:18058867:G:GT	acceptor_loss	1.0000
17:18058867:GG:G	acceptor_gain	1.0000
17:18058964:TGGA:T	donor_gain	1.0000
17:18058965:GGAAG:G	donor_gain	1.0000
17:18058966:GAAGG:G	donor_gain	1.0000
17:18058970:G:GG	donor_gain	1.0000
17:18058970:GTAA:G	donor_loss	1.0000
17:18061971:GAATG:G	donor_gain	1.0000
17:18065175:TGCA:T	acceptor_loss	1.0000
17:18065178:A:AT	acceptor_loss	1.0000
17:18054111:T:TA	acceptor_gain	0.9900
17:18054112:G:A	acceptor_gain	0.9900
17:18054120:A:AG	acceptor_gain	0.9900
17:18054125:A:AC	acceptor_loss	0.9900
17:18054125:A:AG	acceptor_gain	0.9900
17:18054126:G:GG	acceptor_gain	0.9900
17:18054126:G:T	acceptor_loss	0.9900

AlphaMissense

1937 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:18039840:T:C	S126P	1.000
17:18039846:T:A	F128I	1.000
17:18039846:T:C	F128L	1.000
17:18039846:T:G	F128V	1.000
17:18039847:T:C	F128S	1.000
17:18039847:T:G	F128C	1.000
17:18039848:C:A	F128L	1.000
17:18039848:C:G	F128L	1.000
17:18039852:G:A	G130S	1.000
17:18039852:G:C	G130R	1.000
17:18039852:G:T	G130C	1.000
17:18039853:G:A	G130D	1.000
17:18039853:G:T	G130V	1.000
17:18039859:A:C	Q132P	1.000
17:18039860:G:C	Q132H	1.000
17:18039860:G:T	Q132H	1.000
17:18039864:A:C	S134R	1.000
17:18039866:C:A	S134R	1.000
17:18039866:C:G	S134R	1.000
17:18039871:G:A	G136E	1.000
17:18039879:T:C	Y139H	1.000
17:18039879:T:G	Y139D	1.000
17:18039886:T:A	V141E	1.000
17:18045172:T:A	L155H	1.000
17:18045172:T:C	L155P	1.000
17:18045177:G:A	G157R	1.000
17:18045177:G:C	G157R	1.000
17:18045177:G:T	G157W	1.000
17:18045178:G:A	G157E	1.000
17:18045178:G:T	G157V	1.000

dbSNP variants (sampled 300 via entrez): RS1000106486 (17:18038103 C>T), RS1000205438 (17:18055688 C>G), RS1000216411 (17:18062424 C>T), RS1000242523 (17:18064884 A>C), RS1000373605 (17:18051317 C>T), RS1000762022 (17:18054765 C>G), RS1000811519 (17:18047816 T>G), RS1000828145 (17:18055952 T>C), RS1000874858 (17:18046672 A>G), RS1000902940 (17:18066725 G>A), RS1000946756 (17:18054525 A>C), RS1000950764 (17:18053499 A>G), RS1001096676 (17:18039479 G>A,T), RS1001215448 (17:18038977 G>T), RS1001319405 (17:18048684 C>G,T)

Disease associations

OMIM: gene MIM:617699 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

12 associations (top):

Study	Trait	p-value
GCST002539_86	Schizophrenia	2.000000e-08
GCST004771_10	TB-LM or TBLH-BMD (pleiotropy)	1.000000e-10
GCST004946_149	Schizophrenia	7.000000e-10
GCST006803_40	Schizophrenia	3.000000e-08
GCST007201_229	Schizophrenia	8.000000e-09
GCST007201_252	Schizophrenia	9.000000e-10
GCST009600_100	Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)	2.000000e-08
GCST011365_16	Myocardial infarction	5.000000e-09
GCST012228_523	Waist-hip index	4.000000e-08
GCST012230_114	Waist-to-hip ratio adjusted for BMI	3.000000e-08
GCST90020025_1402	Waist-to-hip ratio adjusted for BMI	7.000000e-15
GCST90020027_29	Waist-hip index	6.000000e-16

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004995	lean body mass
EFO:0007788	BMI-adjusted waist-hip ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (4): CHEMBL5169174 (SINGLE PROTEIN), CHEMBL6066842 (PROTEIN-PROTEIN INTERACTION), CHEMBL6066845 (PROTEIN-PROTEIN INTERACTION), CHEMBL6193836 (PROTEIN-PROTEIN INTERACTION)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

16 potent at pChembl≥5 of 26 total, top 16 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.77	Kd	17	nM	CHEMBL5189044
7.10	Kd	80	nM	CHEMBL5177469
7.09	Kd	81	nM	CHEMBL5177469
6.52	Kd	300	nM	CHEMBL5393907
6.30	Kd	500	nM	CHEMBL5411984
5.72	Kd	1900	nM	CHEMBL5195622
5.64	Kd	2300	nM	CHEMBL5197897
5.60	IC50	2500	nM	CHEMBL5411984
5.57	Kd	2700	nM	CHEMBL5435433
5.47	Kd	3400	nM	CHEMBL5405098
5.39	IC50	4100	nM	CHEMBL5177469
5.33	IC50	4700	nM	CHEMBL5177515
5.32	IC50	4800	nM	CHEMBL5191076
5.27	IC50	5400	nM	CHEMBL5208789
5.22	Kd	6050	nM	CHEMBL5579751
5.05	Kd	9000	nM	CHEMBL5414824

PubChem BioAssay actives

16 with measured affinity, of 155 total; 13 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
1-phenyl-1,2,3,4-tetrahydroisoquinolin-5-amine	1851983: Binding affinity to GID4 (124 to 289) (unknown origin) assessed as dissociation constant measured by isothermal titration calorimetry assay	kd	0.0170	uM
N-[4-(1H-benzimidazol-2-yl)cyclohexyl]-2-(1H-indol-2-ylmethylamino)acetamide	1851986: Binding affinity to GID4 (unknown origin) assessed as dissociation constant by surface plasmon resonance assay	kd	0.0800	uM
N-[4-[6-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]-1H-benzimidazol-2-yl]cyclohexyl]-2-[(4-methoxyphenyl)methylamino]acetamide	1985174: Binding affinity to recombinant GID4 (unknown origin) assessed as dissociation constant by surface plasmon resonance assay	kd	0.3000	uM
N-[4-(1H-benzimidazol-2-yl)cyclohexyl]-2-(benzylamino)acetamide	1985174: Binding affinity to recombinant GID4 (unknown origin) assessed as dissociation constant by surface plasmon resonance assay	kd	0.5000	uM
(2R)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-3-(1H-indol-3-yl)-2-[[(2S)-4-methyl-2-[[2-[[(2S)-pyrrolidine-2-carbonyl]amino]acetyl]amino]pentanoyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoic acid	1851980: Binding affinity to GID4 (unknown origin) assessed as dissociation constant	kd	1.9000	uM
(2S)-3-(1H-indol-3-yl)-2-[[(2S)-4-methyl-2-[[2-[[(2S)-pyrrolidine-2-carbonyl]amino]acetyl]amino]pentanoyl]amino]propanoic acid	1985174: Binding affinity to recombinant GID4 (unknown origin) assessed as dissociation constant by surface plasmon resonance assay	kd	2.3000	uM
N-benzyl-2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]acetamide	1985174: Binding affinity to recombinant GID4 (unknown origin) assessed as dissociation constant by surface plasmon resonance assay	kd	2.7000	uM
N-[(4-methoxyphenyl)methyl]-2-[(4-methoxyphenyl)methylamino]acetamide	1985174: Binding affinity to recombinant GID4 (unknown origin) assessed as dissociation constant by surface plasmon resonance assay	kd	3.4000	uM
(2R)-2-[[2-(butylamino)acetyl]amino]-3-(4-tert-butylphenyl)-N-[(2S)-3-(3-methoxyphenyl)-1-(methylamino)-1-oxopropan-2-yl]propanamide	1851982: Inhibition of GID4 (124 to 289) (unknown origin) expressed in Escherichia coli BL21(DE3) using PGLWKS-FITC peptide by competitive-fluorescence polarization binding assay	ic50	4.7000	uM
(E,2R)-2-[[2-(benzylamino)acetyl]amino]-N-[(2S)-1-(methylamino)-3-(4-methylphenyl)-1-oxopropan-2-yl]-5-phenylpent-4-enamide	1851982: Inhibition of GID4 (124 to 289) (unknown origin) expressed in Escherichia coli BL21(DE3) using PGLWKS-FITC peptide by competitive-fluorescence polarization binding assay	ic50	4.8000	uM
(2S)-2-[[(2S)-2-[[2-[(2,4-dimethoxyphenyl)methylamino]acetyl]amino]-2-thiophen-2-ylacetyl]amino]-N-methyl-4-phenylbutanamide	1851982: Inhibition of GID4 (124 to 289) (unknown origin) expressed in Escherichia coli BL21(DE3) using PGLWKS-FITC peptide by competitive-fluorescence polarization binding assay	ic50	5.4000	uM
(2S)-N-[2-[2-[2-[3-[4-[4-[[5-chloro-4-(2-dimethylphosphorylanilino)pyrimidin-2-yl]amino]-3-methoxyphenyl]piperazin-1-yl]-3-oxopropoxy]ethoxy]ethoxy]ethyl]pyrrolidine-2-carboxamide	2111427: Binding affinity to His6-tagged GID4 (114 to 300 residues)(unknown origin) expressed in Escherichia coli Rosetta (DE3) assessed as dissociation constant by ITC analysis	kd	6.0500	uM
N-benzyl-2-(benzylamino)acetamide	1985174: Binding affinity to recombinant GID4 (unknown origin) assessed as dissociation constant by surface plasmon resonance assay	kd	9.0000	uM

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases methylation, increases expression, affects expression, decreases expression	3
Tobacco Smoke Pollution	increases methylation, increases expression	2
Cyclosporine	increases expression	2
GSK-J4	increases expression	1
testosterone enanthate	affects expression	1
bisphenol A	increases expression	1
sodium arsenite	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
2-palmitoylglycerol	increases expression	1
abrine	decreases expression	1
Sunitinib	increases expression	1
Cisplatin	increases expression	1
Methyl Methanesulfonate	increases expression	1
Niclosamide	increases expression	1
Thiram	decreases expression	1
Cadmium Chloride	decreases expression	1

ChEMBL screening assays

48 unique, capped per target: 48 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5106702	Binding	Binding affinity to GID4 (unknown origin) assessed as dissociation constant	Discovery and Structural Characterization of Small Molecule Binders of the Human CTLH E3 Ligase Subunit GID4. — J Med Chem

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SQ01	HAP1 GID4 (-) 1	Cancer cell line	Male
CVCL_XP09	HAP1 GID4 (-) 2	Cancer cell line	Male
CVCL_XP10	HAP1 GID4 (-) 3	Cancer cell line	Male
CVCL_XP11	HAP1 GID4 (-) 4	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.